ReviewActa diabetologica2026

Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes.

Danilo Caponio et al.PubMed ↗Publisher ↗

No numbers read from the abstract.